Please assess the completion status of the following clinical trial:

Trial Title: Manidipine Versus Amlodipine in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients between the ages of 20 and 80 years with uncomplicated essential hypertension are eligible.~* Inclusion criteria requires that patients have either stage I or stage II hypertension (mean sitting systolic Blood Pressure (BP) 140-179 mmHg, diastolic BP 90-109 mmHg).~* The patients are newly diagnosed or known hypertensive subjects who were not taking antihypertensive agents for more than the last 4 weeks.~Exclusion Criteria:~* Patients are excluded from the study if they have any evidence of clinically significant concurrent medical conditions including cardiac, renal, hepatic, gastrointestinal, or endocrinologic disease.~* Patients are also excluded if they have known hypersensitivity or serious drug reactions to Calcium Channel Blockers (CCBs), any evidence of prior deep vein thrombosis, lymphatic disease, or concurrent requirement for medications that could affect Blood Pressure (BP) or salt and water retention (e.g, nonsteroidal antinflammatory drugs, estrogen containing drugs).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Manidipine 20mg (Type: EXPERIMENTAL): 50 patients will be administered orally manidipine 20mg/day after 1\~2 week run-in period
- Amlodipine 10mg (Type: ACTIVE_COMPARATOR): 50 patients will be administered orally amlodipine 10mg/day after 1\~2 week run-in period

Based on this trial design, predict the completion outcome and termination type (if applicable).